Short answer
Organogenesis Holdings Inc. (ORGO) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal third-quarter results ended September 30, 2026 announced by Organogenesis Holdings.
Organogenesis Holdings Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal third-quarter results ended September 30, 2026 announced by Organogenesis Holdings
- Full financial results and management commentary available in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $45.5M, down 70%, with Advanced Wound Care down 73% to $38.2M
- Gross margin fell to 52% from 76%, signaling severe operating deleverage despite operating expenses down 42%
- Adjusted EBITDA loss $22.4M versus $30.1M income, confirming deterioration beyond one-time charges
- Cash, cash equivalents and restricted cash fell to $26.9M from $94.3M, increasing financing and liquidity risk
- 2026 revenue outlook cut to $179.4M-$200.0M, a 65%-68% decline versus 2025 revenue of $564.2M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Organogenesis Holdings Inc. 8-K filings
Get the next ORGO 8-K as it lands
Follow ORGO for push alerts, or ask the research agent what this filing means.